timothy sykes logo
REPL Stock Jumps As FDA Shake-Up Reignites RP1 Hopes Thumbnail
G Google News

REPL Stock Jumps As FDA Shake-Up Reignites RP1 Hopes

JACK KELLOGG•UPDATED MAY. 29, 2026, 9:19 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Replimune Group Inc. stocks have been trading up by 85.04 percent after positive trial data fueled strong investor optimism

Candlestick Chart

Live Update At 09:18:43 EDT: On Friday, May 29, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending up by 85.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Replimune Group Inc. has been trading like a classic event-driven biotech. REPL spent early May grinding in the low $3s, then exploded from about $3.03 to more than $5 in a few sessions once the FDA headlines hit. That is a near-70% swing in days, the kind of volatility short-term traders love but must respect.

Recent daily data show REPL pulling back from the $5.30 area to around $4.68, holding much of the move. Intraday, the stock briefly traded as high as the high $8s in premarket action, signaling aggressive speculative trading and thin liquidity at the open.

Financially, Replimune Group Inc. is still a development-stage biotech. The latest quarterly report shows a net loss of about $70.9M, driven mainly by $53.1M in research and development spending. REPL has no meaningful revenue yet, but it does sit on roughly $269.1M in cash and short-term investments, plus working capital over $230M. A current ratio above 5 shows strong near-term liquidity, which buys Replimune Group Inc. time to advance RP1 and other programs, but negative returns on equity highlight ongoing cash burn. For traders, that mix screams “binary catalyst plus runway.”

Why Traders Are Watching REPL After The FDA Shake-Up

REPL is back on radar screens because the news flow flipped the script on its key regulatory risk. Replimune Group Inc. had been reeling after the FDA rejected its RP1 melanoma therapy despite a positive initial review panel and specialist support. That kind of surprise hit usually crushes sentiment in small-cap biotech. Then the politics stepped in.

Reports that President Trump approved a plan to fire FDA Commissioner Marty Makary — the same commissioner tied to that controversial RP1 rejection — lit a fire under REPL. Traders read it as a signal that the prior call could be revisited, or at least that the gatekeeper who blocked Replimune Group Inc. is no longer secure in that role. The reaction was immediate: REPL shares jumped hard, with premarket prints spiking from the mid-$4s into the high $8s before settling back.

Days later, Makary resigned over a completely different issue — the administration’s move to authorize fruit-flavored e‑cigarettes. Kyle Diamantas, the FDA’s top food regulator, stepped in as acting commissioner. Officially, there is still no new decision on RP1. No fresh label. No fresh PDUFA date. But the whole agency is now in flux, and biotech traders know that leadership shifts often reshape how prior “controversial” calls are viewed.

For momentum traders, REPL sits at the intersection of politics, science, and chart psychology. Replimune Group Inc. has a catalyst-rich story, a chart that shows it can double in days, and a trading crowd looking for an excuse to push it again if any hint of a regulatory reset emerges.

More Breaking News

Conclusion

REPL is a live case study in how fast sentiment can flip when headlines target the people, not just the products, inside the FDA. Replimune Group Inc. went from beaten down near $3 to a sudden squeeze toward $9 in premarket trading, all because traders believed the RP1 melanoma ruling might not be the final word once leadership changed.

The fundamentals of Replimune Group Inc. have not transformed overnight. The company is still pre-revenue, still burning about $66.1M in free cash per quarter, and still posting steep negative returns on assets and equity. What has changed is the perceived regulatory backdrop. A controversial rejection, a fired-then-resigned commissioner, and a new acting leader at the FDA create a fresh narrative that traders will track closely.

For active traders, the lesson from REPL is the same one Tim Sykes drills into his students: “The market doesn’t care about your opinion, only price action and risk management.” As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.”. REPL’s price action is telling you there is real speculation around RP1 and the FDA reset. The risk management side is up to every trader — respect the gap ranges, honor tight stops, and remember this is educational and research content, not a signal to buy or sell Replimune Group Inc. or any other stock.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading REPL

Millionaire's
POV on REPL

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”